Nicola Dalbeth
Dalbeth, Nicola
VIAF ID: 3847145857054422920916 (Personal)
Permalink: http://viaf.org/viaf/3847145857054422920916
Preferred Forms
-
100 1 _
‡a
Dalbeth, Nicola
-
100 1 _ ‡a Dalbeth, Nicola
-
100 1 _
‡a
Dalbeth, Nicola
-
100 1 _ ‡a Dalbeth, Nicola
-
100 1 _
‡a
Dalbeth, Nicola
-
100 0 _
‡a
Nicola Dalbeth
4xx's: Alternate Name Forms (4)
5xx's: Related Names (1)
Works
| Title | Sources |
|---|---|
| Foot pain, impairment, and disability in patients with acute gout flares: A prospective observational study. |
|
| Foot problems in patients with systemic lupus erythematosus; under-reported and under-treated? |
|
| Foot-related pain and disability and spatiotemporal parameters of gait during self-selected and fast walking speeds in people with gout: A two-arm cross sectional study |
|
| Footwear characteristics and factors influencing footwear choice in patients with gout |
|
| Frequency of CYP2C9 polymorphisms in Polynesian people and potential relevance to management of gout with benzbromarone |
|
| Functional and biomechanical characteristics of foot disease in chronic gout: A case-control study |
|
| Gait characteristics associated with the foot and ankle in inflammatory arthritis: a systematic review and meta-analysis |
|
| Gastrointestinal disease and psoriatic arthritis |
|
| Gender and Ethnic Inequities in Gout Burden and Management |
|
| Genetic and Environmental Risk Factors in Hyperuricaemia and Common Gout |
|
| Googling Gout: Exploring Perceptions About Gout Through a Linguistic Analysis of Online Search Activities |
|
| Gout, 2016: |
|
| Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: co-prevalence and implications for clinical practice. |
|
| Gout flare severity from the patient perspective: a qualitative interview study |
|
| Gout, flares, and allopurinol use: a population-based study |
|
| Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout |
|
| Gout in 2010: progress and controversies in treatment |
|
| Gout in Aotearoa New Zealand: are we going to ignore this for another 3 years? |
|
| Gout in Aotearoa New Zealand: the equity crisis continues in plain sight |
|
| Gout Is a Chronic Inflammatory Disease in Which High Levels of Interleukin-8 (CXCL8), Myeloid-Related Protein 8/Myeloid-Related Protein 14 Complex, and an Altered Proteome Are Associated With Diabetes Mellitus and Cardiovascular Disease |
|
| Gout on CT of the feet: A symmetric arthropathy. |
|
| Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank |
|
| Gout--what are the treatment options? |
|
| Gout: Why compare the effectiveness of suboptimal gout management? |
|
| Greater insulin response to acute fructose ingestion among Māori and Pacific people compared to European people living in Aotearoa New Zealand |
|
| GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes |
|
| High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone |
|
| High prevalence of gout in patients with Type 2 diabetes: male sex, renal impairment, and diuretic use are major risk factors. |
|
| How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials |
|
| How Footwear Is Assessed in Patient Reported Measures for People with Arthritis: A Scoping Review |
|
| How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose |
|
| Human Cartilage Homogenates Influence the Crystallization of Monosodium Urate and Inflammatory Response to Monosodium Urate Crystals: A Potential Link Between Osteoarthritis and Gout |
|
| A human leukocyte antigen locus haplotype confers risk for allopurinol-related adverse effects in Caucasian patients with gout |
|
| Hyperuricaemia and gout: state of the art and future perspectives |
|
| Hyperuricaemia and gout: time for a new staging system? |
|
| Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate |
|
| Identification of dairy fractions with anti-inflammatory properties in models of acute gout |
|
| Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability |
|
| The Māori and Pacific specific CREBRF variant and adult height |
|
| A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout |
|
| The natural killer cell: a further innate mediator of gouty inflammation? |
|
| The nomenclature of the basic disease elements of gout: A content analysis of contemporary medical journals |
|
| An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population |
|
| An open-label, 6-month study of allopurinol safety in gout: The LASSO study |
|
| The patient experience of musculoskeletal imaging tests for investigation of inflammatory arthritis: a mixed-methods study |
|
| The patient's experience of gout: new insights to optimize management |
|
| The PTPN22 locus and rheumatoid arthritis: no evidence for an effect on risk independent of Arg620Trp |
|
| A qualitative study to explore health professionals' experience of treating gout: understanding perceived barriers to effective gout management |
|
| A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout |
|
| The relationship between ferritin and urate levels and risk of gout |
|
| The relationship of apolipoprotein B and very low density lipoprotein triglyceride with hyperuricemia and gout |
|
| The renal urate transporter SLC17A1 locus: confirmation of association with gout |
|
| The risk of clinically diagnosed gout by serum urate levels: results from 30 years follow-up of the Malmö Preventive Project cohort in southern Sweden |
|
| The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity |
|
| A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Māori, case and control sample sets |
|
| A subset of natural killer cells is greatly expanded within inflamed joints |
|
| THU0493 Association of the Toll-Like Receptor 4 (TLR4) Gene with Gout |
|
| Time to recognise gout as a chronic disease |
|
| The Toll-Like Receptor 4 (TLR4) Variant rs2149356 and Risk of Gout in European and Polynesian Sample Sets |
|
| Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities |
|
| Tophus resolution with pegloticase: a prospective dual-energy CT study |
|
| Toward development of a Tophus Impact Questionnaire: a qualitative study exploring the experience of people with tophaceous gout |
|
| Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects |
|
| Treat-to-target (T2T) recommendations for gout |
|
| Ultrasound Characteristics of the Achilles Tendon in Tophaceous Gout: A Comparison with Age- and Sex-matched Controls |
|
| Ultrasound Features of the First Metatarsophalangeal Joint in Gout and Asymptomatic Hyperuricemia: Comparison With Normouricemic Individuals. |
|
| Urate crystal deposition and bone erosion in gout: 'inside-out' or 'outside-in'? A dual-energy computed tomography study |
|
| Urate-induced epigenetic modifications in myeloid cells |
|
| Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution |
|
| Urate testing in gout: why, when and how |
|
| Uricase-Deficient Larval Zebrafish with Elevated Urate Levels Demonstrate Suppressed Acute Inflammatory Response to Monosodium Urate Crystals and Prolonged Crystal Persistence |
|
| Use of imaging to evaluate gout and other crystal deposition disorders |
|
| Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis |
|
| Validation of a definition for flare in patients with established gout |
|
| Validation of a radiographic damage index in chronic gout |
|
| Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements |
|
| Variation in gout care in Aotearoa New Zealand: a national analysis of quality markers. |
|
| We read spam a lot: prospective cohort study of unsolicited and unwanted academic invitations |
|
| What is associated with being active in arthritis? Analysis from the Obstacles to Action study |
|
| What is remission in gout and how should we measure it? |
|
| What Is the Evidence for Treat-to-Target Serum Urate in Gout? |
|
| "What say ye gout experts?" a content analysis of questions about gout posted on the social news website Reddit |
|
| What Should Be the Cut Point for Classification Criteria of Studies in Gout? A Conjoint Analysis |
|
| When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy |
|
| Which factors predict discordance between a patient and physician on a gout flare? |
|
| Will Jill come tumbling after? The case for a JAK2-type mutation as a prequel to the connective tissue disorders |
|
| The Work Instability Scale predicts absenteeism in people with gout and suggests a higher risk for those in manual occupations |
|
| "You Don't Have to Be a Drinker to Get Gout, But It Helps": A Content Analysis of the Depiction of Gout in Popular Newspapers |
|
| Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial |
|
| Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study |
|
| প্রত্যুত্তর |
|
